Immune checkpoint inhibitors (ICIs), such as atezolizumab and avelumab, which target PD−L1, pembrolizumab and nivolumab, which target PD-1, and tremelimumab, which targets CTLA-4, have been applied as cancer immunotherapy during the past few decades (50–54). The gene discussed is CD274; the disease is cancer.